LUCIDA Clinical Trial
 

Cross Linking Study
Keratoconus Progression
Cataract Studies
Verisyse Lens Implant
Cornea-Sparing Transplants
Artificial Cornea
Artificial Iris
Cornea Donor
Cornea Transplant Database
Slow Release Drug Implant Study

Frequently Asked Questions
ALK - Course
DSEK / DSAEK / DMEK
DMEK (Experienced DSEK MD's)
Top Hat Transplant
Cornea Conditions & Updates
Board of Directors
Events and Newsletters
Donor Information

Additional Services (new)Foundation News
Life Changing Stories
Contact the Foundation
2008 Golf Outing

 

Refer This Site to a Friend!

Your Mail
Your Name
Friend's Mail
 

Corneal Collagen Cross-linking for Keratoconus and Corneal Ectasia Patients

 Advertisement Information

Foundation participating in first U.S. study of collagen cross-linking (CXL) to assess safety
and effectiveness. A new clinical research investigation has begun to study the benefi ts of corneal collagen cross-linking (CXL) in subjects with progressive keratoconus or corneal ectasia after prior refractive surgery.

These studies are the fi rst in the U.S. of CXL and are designed to assess the safety and effectiveness of CXL for slowing the progression of both of these conditions. Corneal collagen cross-linking is a procedure that involves administering ribofl avin and UVA in carefully selected parameters that strengthen the front layers of the cornea (clear covering of the eye) and avoid damage to the back part of the eye. The ribofl avin and UVA light source that is used for CXL are both investigational in the United States and are not yet approved by FDA. If you qualify and decide to participate in the study, you will receive the ribofl avin and UVA light at no cost. However, there is a fee for the consultation and surgery. Because of the investigative nature of the procedure, most insurance companies will not cover the surgery and you will be required to pay this fee up-front before the procedure is performed.

If you, or someone you know, may be interested in participating in this CXL study, please contact Kathy Kelley, O.D. to learn more about the study or to schedule a consultation examination to see if you qualify for the study. She may be reached at: 317-814-2859 and by e-mail address at kathykelley@pricevisiongroup.net and website is www.cornea.org.

Eligible For The Study?

You have the following in one or both of your eyes or are:

  • 18 years of age or older
  • Have been diagnosed with progressive keratoconus or have had previous vision correction surgery and now have corneal ectasia
  • Vision with contact lenses or glasses is worse than 20/20
  • Corneal thickness greater than 300 microns at the thinnest point
  • If you are female, you cannot be pregnant
  • Can leave your contact lens out for at least 3 months in the eye to be treated
  • If you have keratoconus, you cannot have had previous corneal surgery or Intacs
  • If you have keratoconus, it must have gotten worse in the last two years based on your previous eye exams. You will need to contact your eye doctor or allow us to contact your eye doctor to get your eye exam records for your vision measurements, corneal maps (topographies) and contact lens or glasses prescriptions.

 

Collagen Cross Linking Study Treatment

 

 

Cyclosporine A
9002 N. Meridian Street, Suite 212  -  Indianapolis, IN 46260  -  PH: 317-844-5610  -  FX: 317-814-2806